Neuroscience
(Please refer “Platform technology” section for neuroscience related subjects)
Proposal and validation study of novel therapeutic approaches for rare/intractable diseases associated with neurodegeneration; e.g. ALS, Huntington’s disease and ataxias
New target proposal of innovative modalities (e.g. small molecule, nucleic acid, antibody) for signature features including abnormal RNA/DNA structures, RNA splicing and protein production observed widely in rare/intractable neurological diseases.
Prioritized proposals:
Area of interest:
Amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and related triplet diseases
Research on cellular senescence in neurodegenerative and neurodevelopmental diseases
Calling for research that can contribute to the understanding of involvement of cellular senescence and to future drug discovery targeting cellular senescence in central nervous system diseases.
Areas of interest:
Research on pathophysiology of blood-brain barrier in neurodegenerative diseases
Areas of interest:
Research on non-demented with Alzheimer's neuropathology
Areas of interest:
Research on cell therapy for central nervous system
Areas of interest:
Research on physiological and pathological significance of iron accumulation in neurodegenerative diseases
Areas of interest:
Ideas on novel small molecule therapeutics for congenital muscle diseases such as muscular dystrophies (DMD, DM1, etc.) or congenital myopathies
We are taking applications for ideas to identify novel small molecule compounds that can directly intervene in the causal gene or the pathogenic mechanism based on the genetic mutation for the treatment of congenital muscle diseases. Symptomatic relief approach is out of our focus.
It is preferable if the proposal includes platforms or ideas to predict the clinical effects of the compound appropriately. For example, functional evaluation systems using patient-derived cells such as iPSCs or animal models with precise genetic-features of the disease, etc.
Ideas on novel small molecule therapeutics for hereditary neuropathies including Charcot-Marie-Tooth (CMT) disease, spinal and bulbar muscular atrophy (SBMA), or congenital myasthenic syndrome (CMS), etc.
We are taking applications for ideas to identify novel small molecule compounds that can directly intervene in the causal gene or the pathogenic mechanism based on the genetic mutation for the treatment of hereditary neuropathies. Symptomatic relief approach is out of our focus.
It is preferable if the proposal includes platforms or ideas to predict the clinical effects of the compound appropriately. For example, functional evaluation systems using patient-derived cells such as iPSCs or animal models with precise genetic-features of the disease, etc.
Establishment of neuroinflammation related cellular model/animal model and strategy for patient stratification for inhibitor of innate immune system
Innate immune systems has been suggested as the key pathogenic players in neurodegenerative disorders. Among such innate immune systems, we are interested in cytosolic DNA-sensing, inflammasome and complement activation. We prioritize following proposals:
In particular:
In case Takeda possesses innate immune system inhibitors which an applicant want to utilize, he/she can utilize them.
Novel therapeutic approach to prevent or recover age-related disturbance of neuronal function; e.g. sleep/circadian rhythm, waste clearance, BBB integrity, inflammation, organelle homeostasis, DNA damage
Prioritized proposals:
Examples of approach to prevent or recover age-related disturbance of neuronal function:
Areas of no interest:
Novel methods to enhance clearance system of abnormal proteins from brain, glymphatic system
In many of neurodegenerative disorders including Alzheimer's disease, accumulation of abnormal proteins in the brain is the main pathological change. As a cause of such accumulation, dysfunction of glymphatic system, a brain drainage system, that removes such abnormal proteins from the brain, has attracted attention in recent. Therefore, restoring the dysfunction of this glymphatic system is extremely important to prevent or delay the progress of various neurodegenerative disorders. We want novel innovative basic researches to address that issue.
Areas of interest:
Drug discovery research and Translational research for white matter damage in neurodegenerative disease
Here we call for the idea that materials obtained from patients whose diseases underlie white matter damage are applied for the drug discovery research and the translational research. Proposes for the Omics analyses of white matter damage lesion and/or for the disease modeling that recapitulates neuron-glia interaction with patient-derived cells are welcomed. If needed, technical supports which are necessary to conduct proposed studies may be provided from our research organization upon requests. Our focus areas are Alzheimer’s diseases, Frontotemporal dementia, and rare diseases, such as leukoencephalopathy.
Follow the procedure below to make an application.
* File Format: docx, doc, pdf, File Capacity: up to 1MB
Terms and Conditions for an application to COCKPI-T® Funding
CONTACT
Please contact the COCKPI-T® Funding Office for further information.
* Please be aware that we may not be able to respond to every inquiry.